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Sara K. Tedeschi,1 Bipin N. Savani,1 Madan Jagasia,1 Brian Engelhardt,1 Claudio Anasetti,2
A. John Barrett,3 Stephanie Lee4Squamous cell carcinoma (SCC) is among the most common secondary cancers after allogeneic stem cell
transplantation (allo-SCT). Several types of human papillomavirus (HPV) are causally linked with SCC of
the genital tract and head and neck, and the incidence of these cancers is higher among immunosuppressed
patients compared to immunocompetent patients. In June 2006, a quadrivalent HPV vaccine was approved by
the Food and Drug Administration (FDA) for females aged 9 to 26 years to prevent cervical warts and vulvar,
vaginal, and cervical cancer. FDA approval was granted in October 2009 for males aged 9 to 26 years to
prevent genital warts. The quadrivalent HPV vaccine is now available for off-label use, and may be beneficial
to patients after allo-SCT. It is time to evaluate the immunogenicity and efficacy in preventing HPV-related
squamous cell carcinoma in this population.
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SQUAMOUS CELL CARCINOMA (SSC) IN
IMMUNOSUPPRESSED PATIENTS
The incidence of virus-related malignancies is
increasing among immunosuppressed populations,
such as transplant recipients receiving immunosuppres-
sive therapy and HIV-infected patients. The increased
incidence of cancer in these 2 populations suggests
that immunodeficiency is the common risk factor
predisposing to the heightened risk of malignancy. As
the life expectancy for chronically immunosuppressed
patients continues to rise, malignancy will likely
become an increasingly common complication for these1Long- Term Follow-up Transplant Clinic (LTTC), He-
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6/j.bbmt.2010.03.007patients. Studies of cancer epidemiology among trans-
plant recipients can potentially inform our understand-
ing of which viruses are associated with malignancy in
this population.
Among immunosuppressed patients, the risk for
developing SCC is 64 to 250 times greater than among
the general population [1-3]. Several oncogenic types
of human papillomavirus (HPV) have been implicated
in the etiology of SCC of the female genital tract
and head and neck; of these, HPV 16 and 18 are
most frequently cited [1,2,4]. Significantly higher
levels of HPV DNA have been reported in SCC
from immunocompromised versus immunocompetent
patients, possibly because of higher HPV viral loads
in the former. A recently published meta-analysis
showed that HIV-infected patients and solid-organ
transplant recipients had an increased incidence of
HPV-related cancers, including those of the uterine
cervix, vulva, vagina, penis, anus, oral cavity, and phar-
ynx [2]. The strikingly increased risk of HPV-related
cancers seen in long-term transplant survivors suggests
that even a modest level of immune suppression, if
present for enough time, could increase the risk of
those cancers [1,2,4,5]. Other factors playing a role
in the onset of HPV-related benign and malignant tu-
mors include the degree and duration of immunosup-
pression, age of transplant recipient, and immune
system recovery after transplantation.
Approximately 70% of HPV infections in immu-
nocompetent women are eventually cleared in 1 year.
Natural immunity against HPV involves innate and
adaptive immune responses, predominated by a robust,1033
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lesion regression and generation of serum neutralizing
antibodies [6,7]. Clearance of HPV infection is
diminished among immunocompromised individuals,
and reactivation and progression to neoplastic lesions
become more likely [7-9].
Reactivation of latent DNA viruses has been well
documented in immunocompromised hosts. A large
proportion of these are herpes viruses, such as herpes
simplex, varicella zoster, human herpes virus 6,
Epstein-Barr, and cytomegalovirus. Hepatitis B virus
has also been found to reactivate following allogeneic
stem cell transplantation (allo-SCT). By extension,
we hypothesize that HPV may reactivate and eventu-
ally lead to SCC in long-term survivors of allo-SCT.
In over 90% of HPV-infected healthy individuals
anti-HPV antibodies develop and the virus is cleared
from the serum, indicating resolution of infection.
However, many patients in whomHPV has been elim-
inated from the serum still have detectible HPV DNA
in tissues such as the female genital tract and oral mu-
cosa. After allo-SCT, renal transplantation,HIV infec-
tion, or intensive chemotherapy, dormant HPV may
reactivate in those sites. Late-onset HPV reactivation
may be predicted by monitoring the progressive disap-
pearance of anti-HPVantibodies [1,4,10,11]. Although
it is possible that a newHPV infection could occur in an
immunocompromised host, reactivation of latentHPV
may be an important cause of HPV-related malignan-
cies in this population [1,4].SECONDARY MALIGNANCIES IN ALLO-SCT
RECIPIENTS
Currently, more than 15,000 to 20,000 patients
undergo an allo-SCT annually throughout the world,
with the number of long-term survivors increasing
rapidly. As stem cell transplantation becomes safer,
more than 80% of patients living 2 years after allo-
SCT will become long-term survivors. As patients
age after transplantation, the focus of care moves be-
yond cure of the original disease to the identification
and treatment of chronic complications that can affect
quality of life. Chronic graft-versus-host disease
(cGVHD) has attracted the most attention, but large
database analyses have identified other problems that
occur in sizeable numbers, such as hypothyroidism,
secondary malignancies, pulmonary complications,
congestive heart failure, metabolic syndrome, infertil-
ity, and premature menopause. Large population-
based studies in transplant recipients have shown that
a wide range of cancers could be associated with im-
mune deficiency. Compared to recipients of autolo-
gous SCT, recipients of allo-SCT are at increased
risk for chronic sequelae of transplantation for 2 rea-
sons: complications from the immunosuppressionneeded to prevent GVHD, and the immunosuppres-
sive effect of GVHD itself.
Relative mortality decreases with time from allo-
SCT but remains significantly elevated. One of the
most devastating long-term complications is the devel-
opment of a second cancer, which occurs more fre-
quently than in the general population. In the largest
study of over 28,000 patients after allo-SCT, the risk
for SCC was 5 times higher in patients with a history
of cGVHD than in the general population [12]. In a re-
cent study, 25% of late mortality after allo-SCT was
attributed to treatment-related causes, including 7%
because of secondary cancers in long-term survivors
[13]. The association between HPV and SCC of the
oral cavity, female genital tract, and skin is well estab-
lished in the general population and immunosup-
pressed populations like HIV patients and solid
organ transplant recipients.HPV VACCINE IN IMMUNOSUPPRESSED
PATIENTS, SAFETYAMONG MALES, AND
CLINICAL DATA
Reported prevalence of genital HPV infection in
the general population ranges from 20% to 46%,
and is as high as 64% in clinic-based populations
[1,14-16]. Although HPV infection is common,
studies suggest approximately 90% of infections clear
within 2 years. Interestingly, a study investigating
asymptomatic HPV infection of the oral cavity, using
consensus polymerase chain reaction (PCR) to detect
HPV in oral brushings, revealed HPV DNA in 18%
of samples from renal transplant patients versus 1%
of samples from control patients (P\ .001) [17]. The
fact that HPV 16 and 18 predominate in SCC of the
uterine cervix and head and neck suggests that
the newly developed prophylactic HPV vaccines for
cervical cancer might be useful to prevent SCC. The
success of this strategy would depend upon the propor-
tion of cancers that are HPV 16- or 18-positive, and
therefore preventable by HPV vaccination. The prev-
alence of HPV-related SCC inHIV patients and organ
transplant recipients provides a strong rationale for
HPV vaccination in both male and female recipients
of allo-SCT.Vaccinationmight result in a substantially
decreased incidence of SCC and benign HPV-related
lesions after allo-SCT. Validation of this approach
would require long-term follow up in a large patient
population. An important first step is to document
the immunogenicity of HPV vaccinations in allo-
SCT recipients.
HPV-quadrivalent vaccine is comprised of virus-
like particles (VLP), which are the L1 capsid proteins
fromHPV types 6, 11, 16, and 18.When given accord-
ing to the recommended schedule: 0.5mL intramuscu-
larly in 3 doses, 0, 2, and 6 months, the vaccine has
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HPV infection and HPV-related cervical dysplasia
for up to 5 years. It is FDA-approved for use in females
and males, aged 9 to 26 years, for the prevention of
cervical, vulvar, and vaginal cancer, and genital warts
caused by the aforementioned HPV types. It is esti-
mated that 25% of U.S. females, aged 13 to 17 years,
received the vaccine in 2007. Immunocompromised
patients are at increased risk of latent HPV reactiva-
tion, newHPV infection, and rapid progression to pre-
malignant and malignant lesions. Vaccination might
halt or prevent serious sequelae of infection in this
group. Because these vaccines are prophylactic, it is as-
sumed that maximum effectiveness will be achieved by
administration before exposure to HPV or viral reacti-
vation. As HPV VLP vaccines are highly immuno-
genic—increasing antibody production as well as
stimulating innate and cellular immunity—vaccinating
individuals could offer a boosting effect of previously
acquired natural immunity [10,18,19].
Studies in male adolescents, aged 9 to 15 years,
have shown immune responses to HPV vaccines simi-
lar to those in girls [20]. Giuliano and Palefsky [21]
presented data on the safety and efficacy of HPV-
quadrivalent vaccine in decreasing the incidence of
HPV infection and HPV-related genital disease
among 4065 young men. Guris [22] showed that
7 months after receiving HPV-quadrivalent vaccine,
seroconversion among young men was 98.9%,
99.2%, 98.8%, and 97.4% against HPV 6, 11, 16,
and 18, respectively. A study by Reisinger et al. [23]
showed no vaccine-related serious adverse events
among male recipients of HPV-quadrivalent vaccine.
Data about the safety of HPV vaccination in im-
munosuppressed persons is available for patients with
HIV. Weinberg et al. [24] investigated the safety and
immunogenicity of HPV-quadrivalent vaccine in
HIV-infected children who were being treated with
antiretrovirals. Among 82 subjects who were HPV-
seronegative at baseline, 98%, 99%, 100%, and 95%
of subjects seroconverted for HPV 6, 11, 16, and 18,
respectively, 28 weeks after vaccination. Cell-
mediated immunity, as determined by ELISPOT as-
says, was detected in 36 of 60 HIV-infected children
at 28 weeks after immunization with HPV-
quadrivalent vaccine. There was no significant differ-
ence in the proportion of grade $3 adverse reactions
for vaccine and placebo.
Data on immunogenicity and clinical effectiveness
of quadrivalent HPV vaccine in allo-SCT recipients
are lacking. Despite the several-fold increase in the
overall incidence of cervical dysplasia and squamous
cell carcinoma in patients with SCT, optimal HPV
screening strategies and the effect of HPV vaccination
on transplant recipients are largely unknown. Experi-
ence with other vaccines is rather encouraging in
allo-SCT, although increased dosages or alteredadministration schedules are occasionally required.
Also, shorter intervals between booster vaccinations
might be considered for this group of patients. Thus,
although future recipients of SCT will likely have
received the HPV vaccine at a younger age, boosters
after SCT will likely still be required for optimal
protection.
Despite the safety and theoretic efficacy of the vac-
cine, several questions remain before HPV vaccination
can be proposed as the standard of care post-SCT:
How long will the vaccine confer protection in immu-
nosuppressed patients? How effective is the current
vaccination schedule in immunosuppressed patients?
To investigate whether the quadrivalent, recombinant
HPV vaccine reduces late morbidity and mortality
from secondary SCC in long-term survivors after
allo-SCT, ideally a large, multicenter, randomized,
placebo-controlled study would be conducted given
the low absolute rate of secondary SCC. The protec-
tive effect against malignant and premalignant lesions
will only be measurable 5 to 10 years after vaccina-
tion—the time frame during which HPV-related can-
cers are likely to develop. Now is an opportune time to
examine the immunogenicity and long-term efficacy of
HPV vaccination in SCT recipients.ACKNOWLEDGMENTS
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